Q&A with ASTRO's Dr. David Beyer

Over 1000 Total Lots Up For Auction at Three Locations - NJ Cleansweep 03/02, NJ 03/08, CA 03/12

Q&A with ASTRO's Dr. David Beyer

par Sean Ruck, Contributing Editor | September 26, 2017
Rad Oncology Radiation Therapy

HCB News: How would you describe the shift in the perception of radiation oncology? What is ASTRO’s role in this evolution?
DB: Radiation oncology may have once been considered a niche field, buried deep in the basement. Today, we are a vibrant specialty and an equal partner in cancer care — and we work to live that every day. ASTRO is pushing for radiation oncologists around the country to act as leaders in clinical care so that both patients and referring physicians know we are caring for the whole patient. We can only do that with our hands on the patient and not on the computer mouse. As we work to elevate the profile of our field, we want those outside of our specialty to recognize our value to the house of medicine — as an innovative specialty that is generating impactful science, providing advice and input to physician peers on oncology issues and reflecting the diversity of the patients we serve.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

HCB News: How does a medical society like ASTRO support collaborative, multidisciplinary research? Are there tangible ways to break down silos in cancer research?
DB: Just this year, ASTRO’s Science Council created and publicized a research agenda of the big questions that we see. Many of these issues are in areas that cross disciplines, such as drug development and delivery, genomics, immunotherapy and physics, to name a few. By identifying these key areas, we hope to stimulate the next generation to begin their research careers without ever seeing a silo or walls limiting their creativity. Last spring, ASTRO convened a meeting of drug researchers, radiation oncology researchers, governmental researchers and regulators to identify new ways we can work together. We have been working on this effort, but there is much more to do.

HCB News: What is the role of health policy in this discussion? In what ways does the turbulence in the American health care landscape affect cancer care? Is ASTRO doing anything to stay in front of these changes?
DB: One of our goals is to remain vigilant in our efforts to help craft health policy that supports radiation oncologists’ ability to succeed—which will result in better outcomes for our patients. We remain vocal advocates for access to affordable care, particularly in rural and medically underserved areas. For example, we are working with policy stakeholders such as the Centers for Medicare and Medicaid Services (CMS) to create and implement new Alternative Payment Models (APMs). We continue to advocate for quality and safety through our APEX accreditation program and RO-ILS.

As the country is going through the uncertainty of health care reform, we are also committed to helping craft the rules under which we all work. We have already been frequent visitors on Capitol Hill and with CMS and the Center for Medicare & Medicaid Innovation (CMMI) to confer on relevant policy questions. We are working to increase our participation on advisory panels such as the MedCAC (Medicare Evidence Development & Coverage Advisory Committee), where several radiation oncologists have served, and on new panels such as PTAC (Physician-Focused Payment Model Technical Advisory Committee) as they begin their work.

The landscape is turbulent, but as long as we are advocating for high quality and safe care for our patients, then we believe the specialty will remain vibrant.
Back to HCB News

You Must Be Logged In To Post A Comment